Ongoing research suggests that a better understanding of GR nuclear functions and cofactors in ALL and use of inhibitors against epigenetic cofactors or enzymes controlling posttranslational modifications in combination with GCs could be of therapeutic value in high-risk ALL cases. Here, NR3C1 is linked to acute lymphoblastic leukemia.